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Abstract Despite the fact that an unprecedented series of
new discoveries in neurochemistry, neuroimaging, genetics
and clinical pharmacology accumulated over the last
20 years has signiﬁcantly increased our current knowledge,
theunderlyingmechanismofthemigraineheadacheremains
elusive. The present review article addresses, from early
evidence that emerged at the end of the nineteenth century,
the role of ‘antidromic vasodilatation’ as part of the more
general phenomenon, currently deﬁned as neurogenic
inﬂammation,intheuniquetype ofpain reportedbypatients
suffering from migraine headaches. The present paper
describes distinctive orthodromic and antidromic properties
of a subset of somatosensory neurons, the vascular- and
neurobiologyofpeptidescontainedintheseneurons,andthe
clinical–pharmacological data obtained in recent investiga-
tions using provocation tests in experimental animals and
human beings. Altogether, previous and recent data under-
score that antidromic vasodilatation, originating from the
activation of peptidergic somatosensory neurons, cannot yet
be discarded as a major contributing mechanism of the
throbbing head pain and hyperalgesia of migraine.
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Early studies
Pioneering physiological studies at the end of the nine-
teenth century through the beginning of the twentieth
postulated the existence of a double function of a subset
of sensory, afferent neurons with cell bodies located
in the dorsal root ganglia (DRG). We owe Bayliss [1]
for the experiments, performed principally on the
dog, and his brilliant interpretation that led him to
conclude:
1. ‘There are nerve-ﬁbres in the posterior roots of the 5th,
6th, and 7th lumbar and 1st sacral nerves, excitation of
which, when cut away from the spinal cord, gives rise
to vascular dilatation in the hind-limb of the same side.
The excitation may be either electrical, mechanical,
chemical, or thermal, and of these, mechanical exci-
tation is most effective.’
2. ‘They do not degenerate when cut between spinal cord
and posterior root ganglion, hence they are not spinal
efferent ﬁbres. They do degenerate when posterior root
ganglia are extirpated, hence their trophic centres are
in these ganglia.’
3. ‘They are, in fact, identical with the ordinary sensory
afferent posterior root-ﬁbres; the name ‘‘antidromic’’
is suggested for the process by which nerve-ﬁbres
convey impulses in a direction contrary to that
assumed by the Bell–Majendie law, when such
impulses produce effects in the organs at the origin
of such ﬁbres, e.g. when afferent ﬁbres excited at their
ends in the central nervous system produce vascular
dilatation at their peripheral ends in the tissues of the
body.’
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The biochemical substance(s) that mediates the ﬂare
response to injury or to capsaicin applied to the human
skin has remained unidentiﬁed for more than a century.
The discovery that a subset of primary sensory neurons
express, and, from their peripheral terminals, release
vasoactive neuropeptides has pointed to these substances as
the mediators of the ﬂare evoked by the activation of axon
reﬂexes [2]. The tachykinin substance P (SP) and neurok-
inin A (NKA) and the longer 37 aminoacid peptide, cal-
citonin gene-related peptide (CGRP), are all found in a
subset of neurons of the DRG, vagal and trigeminal (TG)
ganglia. During the last 20 years cloning of their receptors
and identiﬁcation of selective antagonists [3–6] have
provided powerful tools to unravel their functions when
liberated from central and peripheral endings of pseudo-
unipolar somatosensory neurons. The role of both tach-
ykinins and CGRP released in the dorsal spinal cord at the
level of the lamina I and II remains uncertain, as they do
not seem to give a major contribution to nociceptive
information or hyperalgesia. In contrast, in rodents com-
pelling evidence indicates that SP/NKA mediate the
plasma protein extravasation, and CGRP is responsible for
most of the vasodilatatory component of the inﬂammatory
response evoked by stimulation of sensory nerve endings in
peripheral tissues [2]. The observation that the CGRP
receptor antagonist, telcagepant [7], markedly reduced the
increase in forearm skin blood ﬂow evoked by topical
application of capsaicin [8] points to CGRP as the major, if
not the sole, mediator of the neurogenic dilator response
resulting from sensory nerve terminal activation in humans.
Hyperalgesia and ﬂare
About 40 years after the seminal observation of William
Bayliss, Lewis [9] addressed the issue of how the skin
surrounding an injured site becomes painful, by hypothe-
sizing the existence of ‘‘nocifensor’’ nerve ﬁbres. Accord-
ing to Lewis’ hypothesis, these ‘specialized’ ﬁbres would
detect information about a localized injury and spread this
information both to surrounding sensory afferents that
encoded pain, thereby causing hyperalgesia, and to blood
vessels to cause local dilatation leading to the ﬂare
response (reddening of the skin). With the term ‘‘axon
reﬂex’’ Lewis [9] depicted the hypothesis that from one
portion of a widely branching sensory ﬁbre which
responded to the injury, action potentials propagated anti-
dromically to collateral nerve ﬁbres where they liberated a
chemical substance, which in turn caused the ﬂare and
enhanced sensitivity of other sensory axons responsible for
pain. This proposal originally generated by the study of
injurious stimuli [9] was substantially conﬁrmed by other
authors [10–12], who used capsaicin as the stimulus which
promotes vasodilatation and hyperalgesia.
The hypothesis [13–15] that inputs from C nociceptors
lead to presynaptic depolarization, strong enough to initiate
action potentials, which antidromically propagate to the
peripheral receptive ﬁelds of these ﬁbres, is substantially
rejected by the observation that blocking central nerve
trunks [10] or cutting nerves [1, 9] does not block the ﬂare.
The block of the proximal nerve with local anaesthetic did
not prevent the spread of ﬂare around the injection site, but
did prevent the development of hyperalgesia some hours
later [10]. Thus, central nervous system neurons encoding
painful inputs must receive some decisive input from the
nerve ﬁbres of the hyperalgesic region during the early
phases of exposure to the stimulus. The proposed model
[10] was that chemospeciﬁc peripheral nerve ﬁbres either
widely branching or functionally coupled together in the
periphery may sensitize low- and high-threshold mecha-
noreceptive interneurons in the dorsal horn. A subcategory
of mechanically sensitive C-ﬁbre neurons may directly
contribute and also facilitate Ad-ﬁbre neurons to produce
hyperalgesia [16].
It should be underlined that subsequent studies which
used thermography [11] or laser Doppler ﬂowmetry [12]t o
determine the area of ﬂare/vasodilatation after the injection
of capsaicin into the human skin showed a much larger area
than that previously identiﬁed by the sole visual inspection
of the area of reddening. A strict correspondence between
the areas of ﬂare, and mechanical and heat hyperalgesia
induced by intradermal capsaicin injection, suggested that
all three phenomena are the consequence of neural factors
that operate peripherally [11, 12]. Nevertheless, whether an
intimate functional link exists between areas of ﬂare and
mechanical and heat hyperalgesia is still controversial. In
addition, the identity of the chemical mediator(s) that
directly or indirectly establishes, or contributes to, hyper-
algesia in the area of the axon ﬂare, and particularly if this
may be considered CGRP or not, remains to be determined.
For example, in rats, if CGRP injection in the dorsal skin
was not found to cause hyperalgesia [17], repeated
intraplantar injections of low doses of CGRP have been
shown to induce hyperalgesia [18].
Allodynia, hyperalgesia and migraine
On the basis of the progress of allodynia in a migraine
patient, it was proposed [19] that during a migraine attack,
soon after the activation of peripheral nociceptors, these
same neurons become sensitized, and the barrage of
impulses deriving from peripheral input recruits second
and third order neurons, then spreading to the contralateral
side of the head and to ipsilateral anatomical sites at a
distance from the head. Experimental evidence and related
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can be applied to migraine, postulating that the sensitiza-
tion process, which eventually results in allodynia and
hyperalgesia, initiates at peripheral sites. Although not
conclusively demonstrated, but suggested by positron
emission tomography neuroimaging studies [20], the onset
of a migraine attack might take place in and extracranial
deep brain structures. Although in experimental animals
there is no evidence for mechanical activation of noci-
ceptive afferents during vessels dilatation, novel clinical
ﬁndings suggest that the headache phase depends on
nociceptive input from perivascular sensory nerve termi-
nals, as shown by: (1) the temporal association of pain with
dilatation of intra- and extracranial arteries; and (2) the
temporal association of pain resolution by antimigraine
drugs with constriction of dilated extracranial arteries [21].
This, together with a series of headache/migraine provo-
cation tests in healthy volunteers and migraine patients, has
led to the conclusion that migraine can be explained to
patients as ‘a disorder of the brain, and that the headache
originates in the sensory ﬁbres that convey pain signals
from intracranial and extracranial blood vessels’ [22].
Features and mechanisms of neurogenic inﬂammation
Tachykinins
The introduction of experimental neurobiology and phar-
macology of capsaicin, with its unique features to activate
and desensitize a speciﬁc subset of C- and Ad-ﬁbre noci-
ceptors, has been instrumental for the identiﬁcation of the
key contribution of these neurons to neurogenic inﬂam-
mation [2]. The major vascular action of CGRP action
(conserved throughout the mammal species, including
man) is the vasodilatation of large and small size arteries
via direct activation of the calcitonin receptor-like receptor
(CLR) associated to the receptor activity-modifying pro-
tein-1 (RAMP1) [4], which are primarily located on the
plasma membrane of arterial smooth muscle cells. Other
functions of CGRP, however, irrelevant for the present
discussion, are directed to relax smooth muscle cells in
certain tissues, including those of the urinary tract or the
intestine [2]. Species-speciﬁc actions, some of which are of
proinﬂammatory nature, are mediated by SP and NKA
through the activation of their receptors, namely the NK1,
NK2 and NK3 receptors. These include plasma protein
extravasation evoked by activation of NK1 receptors on
endothelial cells of postcapillary venules, contraction of
iris or bronchial smooth muscle, and secretion from sero-
mucous glands. SP has also been proposed to accumulate
neutrophils [23], activate macrophages [24], and stimulate
mast cells. However, it should be underlined that there
is no conclusive proof that endogenously released tach-
ykinins (e.g. after capsaicin administration) can, through
a receptor mediated mechanism, act on these pro-inﬂam-
matory cells. Rather, there is evidence that some of these
actions are either indirect or mediated by a receptor-inde-
pendent action [25].
Irrespective of the undisputable role of SP in rodent
neurogenic plasma protein extravasation, the failure of
NK1 receptor antagonists in the acute migraine attack
convincingly discarded the hypothesis that meningeal
plasma protein extravasation could be the underlying
mechanism of migraine [26]. The ability to detect the
capsaicin-evoked release of CGRP and the failure to
measure that of SP from slices of human iris in vitro [27]
and the observation that capsaicin injection into the human
skin causes ﬂare (mediated by CGRP) but not wheal
(mediated by SP) [10] suggest that in humans SP is not
released from peripheral endings of somatosensory neu-
rons, or that it is released in amounts not sufﬁcient to
provoke the effects that it evokes in rodents.
Calcitonin gene-related peptide
Thus, after excluding the contribution of sensory tachyki-
nins, which in humans do not seem to exert any major role,
the residual component of the neurogenic inﬂammatory
response that might be implicated in the pathophysiology
of the migraine attack is conﬁned to CGRP and its vaso-
motor effects. The seminal observation that CGRP is
increased in blood deriving from the cranial circulation
during migraine attacks [28] and more importantly the
ability of three chemically unrelated CGRP receptor
antagonists to ameliorate the pain and the associated
symptoms of the migraine attack [29–31] supports the view
that CGRP-dependent effects are of paramount importance
in the mechanism of migraine. In the context of the present
article, the hypothesis that antidromic release of CGRP
from peripheral terminals of trigeminal somatosensory
neurons and its ensuing vascular effects play a role in
migraine will be addressed.
Molecular targets of migraine triggers
TRPV1 stimulating agents
The importance of the vasodilator component of neuro-
genic inﬂammation in migraine is further supported by the
observation that known triggers of migraine attacks pro-
duce neurogenic vasodilatation in experimental animal
models. A large and variable number of stimuli may pre-
cipitate migraine [32]. Among them, stress with the ensu-
ing post-stress phase is often described by patients as
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in a stressful condition was found to increase dural vascular
permeability in a manner dependent on NK1 receptor, thus
indicating the involvement of neurogenic inﬂammation
[33]. In this model, CGRP-mediated responses were
not measured, but due to the fact that upon stimulation
of capsaicin-sensitive neurons both SP and CGRP are
invariably co-released, it is possible that exposure to stress
also results in the release of CGRP and CGRP-dependent
vasodilatation.
Perfumes/odours, alcoholic beverages and cigarette
smoke are also reported by about 30–40% of the patients as
effective triggers of migraine attacks [32]. A few years ago
ethanol was identiﬁed as a stimulus of the transient receptor
potential vanilloid 1 (TRPV1) channel [34]. TRPV1, also
known as the capsaicin receptor, belongs to a larger family
of non-selective cation channels responsible for a series
of pleiotropic biological responses [35]. TRPV1 is co-
expressed with the neuropeptides, SP and CGRP in
somatosensory neurons [36], and therefore its stimulation
by capsaicin and other stimuli results in neuropeptide
release and neurogenic inﬂammatory responses [2]. Etha-
nol action on TRPV1 appears to be indirect, as ethanol
reduces the threshold temperature for TRPV1 activation
(normally 42–43C) by 8C to 34–35C. Therefore, in the
presence of ethanol, the normal body temperature of 37C
is sufﬁcient to activate the channel and to promote neuro-
genic inﬂammatory responses [34]. This unique property of
ethanol may explain the burning quality (similar to that
evoked by capsaicin) of the pain provoked by alcoholic
beverages or tinctures when applied to wounded cutaneous
surfaces or to oral and other types of mucosa. In meningeal
arterial vessels of the guinea pig, the administration of an
amount of alcohol corresponding to that contained in 3–4
glasses of wine produced a TRPV1-mediated and CGRP-
dependent vasodilatation that has been suggested to explain
the ability of alcoholic beverages to trigger migraine in
susceptible individuals [37].
TRPA1 stimulating agents
AsubstantialproportionofneuronsthatexpressTRPV1also
express the transient receptor potential ankyrin 1 (TRPA1)
channel [38]. Among TRP channels, TRPA1 shows the
unique feature to be activated (and accordingly, it has been
proposed as a sensor of) by by-products of oxidative and
nitrative stress [39]. Thus, exogenous agents such as form-
aldehyde, acrolein or crotonaldehyde (contained in cigarette
smoke or environmental pollution) [40, 41], or endogenous
compounds generated by the peroxidation of plasma
membrane phospholipids, such as 4-hydroxynonenal and
4-oxononenal [42] are powerful stimulants of TRPA1.
Umbellularia californica Nutt. is a tree indigenous to
southwesternOregon andNorthernCalifornia.As knownby
native Americans, and ﬁrst reported more than 100 years
ago [43], exposure to U. californica (commonly known
as the ‘headache tree’) can trigger violent headache cri-
ses [44].We recently described a case of cluster headache-
like attacks triggered by the inhalation of the scent of
U. californica [45]. However, the xenobiotic(s) contained
in the plant scent, responsible for triggering headaches
in migraineurs and in cluster headache patients, is
unknown.
U. californica contains, as a major volatile constituent,
umbellulone,amonoterpeneketone,withastrong,camphor-
likeodour,whichexertsirritanteffectsinlaboratoryanimals
[44]. Umbellulone has recently been identiﬁed as an agonist
of either the heterologously expressed human TRPA1 or
native rat and mouse TG neurons TRPA1 [46]. It has also
been reported that umbellulone application to the rat nasal
mucosa causes, through TRPA1 stimulation, a CGRP-
dependent meningeal vasodilatation [46]. These ﬁndings,
and the observation that intranasal application of acrolein or
oftheTRPA1agonist,allylisothiocyanate,evokesasimilar,
CGRP-mediated meningeal vasodilatation [47], support the
hypothesis that ammonium chloride, chlorine, cigarette
smoke, and formaldehyde, all known triggers of migraine or
cluster headache [32, 48–51], precipitate pain attacks by
theirrecentlyidentiﬁedabilitytotargetneuronalTRPA1and
thereby releasing CGRP [39, 40, 52, 53]. Thus, emerging
evidence supports the hypothesis that some triggers of
migraine, and possibly cluster headache, act via a general
mechanism which, by stimulating perivascular sensory
nerve endings, releases the vasodilator peptide CGRP. All
thesevariousandchemicallyunrelatedcompoundsstimulate
TRPA1 or TRPV1 on cranial perivascular nerve ﬁbres to
activate a ﬁnal common pathway, which is identical to that
previouslyproposedasoccurringintheskinfollowingtissue
injury [1, 9] or exposure to capsaicin [10, 11], and which
recognizes antidromic release of CGRP and its vasodilata-
tion/ﬂare effect as the ﬁnal step (Fig. 1).
Neurogenic vasodilatation and migraine
Vasodilatation
The seminal proposal by Graham and Wolff [54] who
associatedtheheadachephaseofthemigraineattackwiththe
throbbing dilatation of the superﬁcial temporal artery, and
pain termination by ergotamine with a dramatic reduction in
arterial pulsatility, has been subsequently challenged by the
failure to measure any signiﬁcant vasodilatation during
migraine attacks either by using a laser Doppler ﬂowmetry
technique [55] or more recently in a magnetic resonance
angiography (MRA) study [56]. However, more recent
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imaging technique [21] during headache and migraine
attacks provoked by a 20 min CGRP infusion, suggest the
reconsideration of the rejection of vasodilatation as a major
contributing mechanism of migraine pain, and the resulting
dismissal of Wolff’s hypothesis. In migraine patients, infu-
sion of CGRP-evoked delayed, unilateral migraine pain
associated with dilatation of the middle meningeal artery
(MMA, with a more pronounced dilatation) and of the
middle cerebral artery (MCA, with a less pronounced dila-
tation) on the pain side, but not on the pain-free side. In
patients with bilateral migraine pain, bilateral dilatation of
both the MMA and MCA was recorded [21]. Thus, the
migraine pain was associated with arterial vasodilatation
bothwithrespecttothetimecourseandthesideoftheevent.
The series of enlightening clinical provocation tests in
healthyvolunteersandmigrainepatientsbytheCopenhagen
grouphasgreatlycontributedtoourcurrentunderstandingof
the role of CGRP and vasodilatation in migraine. CGRP
infusion caused headaches and migraine-like attacks in mi-
graineurs [57], although this effect, as those of other vaso-
dilators, occurs when presumably the concentration of the
vasodilator substance in blood is low or negligible. Further
studiesshowedthatinhealthyvolunteers,theCGRPreceptor
antagonist, olcegepant, signiﬁcantly reduced the immediate
anddelayedheadacheevoked byCGRPadministration[58].
If the ability of CGRP receptor activation or inhibition to
provoke or abort, respectively, headache and migraine
attacks has been well established, the site of action of CGRP
toevokeheadpainisunclear.Itispossiblethattheabsenceof
or the very limited [59] dilation of MCA evoked by CGRP
infusion is due to the inability/poor ability of exogenously
administered CGRP to cross the blood–brain barrier (BBB),
and therefore to act in the intracerebral vascular compart-
ment [60]. This conclusion is further supported by the
observation that olcegepant (a CGRP antagonist of peptoid
nature, which does not easily cross the BBB) [61, 62] had no
effect on the slight increase in MCA vasodilatation, but
inhibited the much larger dilation of extracerebral arteries,
suchasthesuperﬁcialtemporalandtheradialarteries[58].A
mechanism similar to that found in patients with migraine
without aura (MO) should occur in patients with migraine
with aura (MA), as CGRP infusion triggered migraine-like
attacks (some with aura) in patients suffering exclusively
from MA [63]. However, CGRP infusion failed to induce
migraine attack in patients affected by the familial hemi-
plegicmigraine(FHM)withknownmutationsinthecalcium
channel, voltage-dependent, P/Q type, alpha 1A subunit, the
ATPase, Na
?/K
? transporting, alpha 2 (?) polypeptide
genes or without known mutations [63]. Although the
obviously small number of patients with FHM limits the
robustness of the conclusion, these data suggest differences
in the mechanism of head pain between patients with FHM
and patients with MO/MA.
An emerging role for CGRP and neurogenic vasodilata-
tioninchronicmigraineissuggestedbyﬁndingsobtainedby
the injection of botulinum neurotoxin type A (BoNTA) into
the rat craniofacial muscles, a procedure that decreased
mechanical sensitization mediated by glutamate and CGRP-
induced neurogenic vasodilatation [64]. Similar observation
was previously obtained in the human skin where pretreat-
ment with BoNTA reduced the pain and the neurogenic
vasodilatation evoked by topical capsaicin application [65].
Thus, preclinical and clinical evidence suggests that BoN-
TA, recently introduced for the treatment of chronic
migraine and medication overuse headache [66–68], may
exert its beneﬁcial effect by decreasing mechanical sensi-
tivity of cranial muscle nociceptors through inhibition of
glutamate release and by attenuating the release of CGRP
from muscle nociceptors.
Vasoconstriction
The antimigraine effect of sumatriptan has originally been
linked to its ability to produce a rather selective contraction
Fig. 1 Neurogenic vasodilation in migraine. Activation of peptider-
gic trigeminal sensory neurons results in the release of calcitonin
gene-related peptide (CGRP), which acting at the CGRP-like receptor
(CLR) coupled to receptor activity-modifying protein-1 (RAMP1),
relaxes smooth muscle cells of intra- and extracranial arteries.
Exogenous or endogenous agonists of transient receptor potential
vanilloid 1 (TRPV1) or ankyrin 1 (TRPA1) promote the release of
CGRP. Prostaglandins (PGs), bradykinin (BK) or other proalgesic
agents, either directly via activation of their speciﬁc G protein
coupled receptors (GPCR) or indirectly (through channel activation)
also contribute to neuropeptide release. Nitric oxide (NO) generated
from glyceryl trinitrate (GTN) acts downstream to CGRP to evoke
vasodilatation and probably headache. Neurogenic vasodilatation in
addition to cause the headache may also contribute to neuronal
sensitization. Sumatriptan and other triptans inhibit CGRP release
acting at prejunctional serotonin 5-HT1D receptors or evoke arterial
vasoconstriction via stimulation of 5-HT1B receptors on vascular
smooth muscle. Botulinum neurotoxin type A (BoNTA) has also been
shown to inhibit CGRP release
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and other tissues [69]. The hypothesis that meningeal neu-
rogenic plasma protein extravasation could be responsible
for the migraine attack [70], was strengthened by the ability
of triptans to inhibit this type of inﬂammatory response in
rodents, probably by reducing the release of SP/NKA [71].
TriptanshavealsobeenshowntoinhibitthereleaseofCGRP
[71–73]. These mechanisms cannot be dismissed when
considering the antimigraine effect of triptans. However, if
theactionoftriptanswaslimitedtothepresynapticinhibition
of sensory neuropeptides, they should act as inhibitors of
neurogenic vasodilatation or, in other terms, as indirect
vasoconstrictors. As a consequence, triptans should not
reduce the vasodilatation evoked by CGRP which, via the
intracellular increase in cyclic adenylyl monophosphate,
directlyrelaxesthearterialsmoothmuscle.InCGRP-evoked
attacks,ameliorationofthedelayedmigrainebysumatriptan
administration was associated with the contraction of the
dilated MMA, but not of the dilated MCA [21]. Thus, reso-
lutionofthemigraineattackbysumatriptanwaslinkedtothe
selective vasoconstriction of the extracranial MMA [21].
TheproposalthatexogenousCGRPdoesnotdilatetheMCA
and that olcegepant does not inhibit the vasodilatation of the
arterybecauseneitherCGRPnorolcegepantcaneasilycross
theBBB[60]couldbeextended tosumatriptan.Itsfailure or
poorcapacitytoconstrict bothnormal anddilatedMCA [21,
60] could be due to its poor ability to cross the BBB [74].
During a migraine attack occurring from several minutes
to hours after the end of CGRP infusion, it is possible that
exogenous CGRP (likewise many other vasodilator sub-
stances) targets a hitherto undeﬁned central site that
eventually results in sensory nerve activation and the
release of endogenous CGRP. Under these circumstances,
sumatriptan, acting on presynaptic 5-HT1D receptors
might have inhibited a delayed CGRP release. However,
this conclusion is challenged by three additional observa-
tions. Firstly, sumatriptan caused constriction of the MMA,
non-dilated because it is either under baseline conditions
[60] or on the pain-free side during a monolateral migraine
attack [21]. Under these two conditions presumably there is
no release of CGRP from perivascular sensory nerve ter-
minals. Secondly, in healthy volunteers sumatriptan was
found to reduce the early increase in MMA circumference,
a response that, in contrast with the vasodilatation associ-
ated with the migraine-like attack observed in migraine
patients, is closely associated with CGRP administration
[60]. Thirdly, the high afﬁnity CGRP receptor antagonist,
olcegepant, which effectively reduced spontaneous [31]
and CGRP-provoked [58] attacks, did not ameliorate
migraine attacks evoked by the direct vasodilator, nitric
oxide (NO) donor, and glyceryl trinitrate (GTN) [75]. This
latter ﬁnding was properly interpreted with the hypothesis
that GTN induces migraine, rather than by releasing
CGRP, by a mechanism that operates downstream with
respect to CGRP. The hypothesis implies that, if suma-
triptan blocks headache and migraine attacks evoked by
GTN [76–80], the drug should work by blocking not, or not
solely, the release of CGRP by an inhibitory presynaptic
action on sensory nerve terminals, but rather, or addition-
ally, through some downstream and very basic mechanism,
such as that activated by NO donors.
Conclusion
Despite unprecedented advancement in migraine knowledge,
essential issues remain unresolved in order to establish the
vascular or non-vascular origin of migraine pain. Various
ﬁndings challenge the vascular hypothesis. These, among
others, include: (1) the still undetermined mechanism that,
initiated by GTN and many other vasodilators, only after a
signiﬁcanttime delay fromtheir administration, provokesthe
migraine-like attack; (2) inconsistencies between the degree
ofvasodilatationandtheseverityoftheheadache[81,82];(3)
the discrepancy between the potential of generating head-
aches between two similar vasodilatatory peptides [83, 84];
(4) the apparent lack of a simple correspondence between the
subjective experience of throbbing pain and the arterial pulse
[85]. In addition, current evidence cannot exclude that vaso-
dilators used to trigger migraine attacks do not act via their
vasoactive action, but rather through subtle changes in the
brain and brainstem and that CGRP itself may act not, or not
exclusively, at the vascular level, but at additional peripheral
or central sites [86]. However, ﬁndings that emerge from
studies in experimental animals, healthy volunteers, and
migrainepatientsthroughtheuseoftheprovocationmodelof
migraine underscore that ‘antidromic vasodilatation’, as
deﬁned more than a century ago by the imaginative vision of
pioneers in physiological, neurobiological and pharmaco-
logical investigation, cannot as yet be discarded.
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